Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de pesquisa sobre como o concizumabe funciona para você se você tem hemofilia A ou B com ou sem inibidores (Explorer10)

17 de setembro de 2026 atualizado por: Novo Nordisk A/S

Estudo aberto investigando eficácia, segurança e farmacocinética da profilaxia com concizumabe em crianças menores de 12 anos com hemofilia A ou B com ou sem inibidores

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Visão geral do estudo

Status

Ativo, não recrutando

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Estimado)

153

Estágio

  • Fase 3

Acesso expandido

Não está mais disponível fora do ensaio clínico. Consulte registro de acesso expandido.

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Algiers, Argélia, 16000
        • Haematology and Blood Bank Department
      • Constantine, Argélia, 25000
        • CHU Constantine BEN BADIS/ Hematology department
      • Plovdiv, Bulgária, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
      • Sofia, Bulgária, 1527
        • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
      • Varna, Bulgária, 9010
        • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
      • Banja Luka, Bósnia e Herzegovina, 78000
        • University Clinical Center of Republic Srpska (545)
      • Tuzla, Bósnia e Herzegovina, 75000
        • University Clinical Centre Tuzla
    • British Columbia
      • Vancouver, British Columbia, Canadá, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Hamilton, Ontario, Canadá, L8N 3Z5
        • McMaster Children's Hospital
      • Barcelona, Espanha, 08035
        • Hospital Vall d'Hebron
      • Madrid, Espanha, 28046
        • Hospital Universitario La Paz
      • Málaga, Espanha, 29009
        • Hospital Regional Universitario de Málaga
    • Murcia
      • El Palmar, Murcia, Espanha, 30120
        • Hospital Virgen de la Arrixaca - Hematología
    • California
      • San Diego, California, Estados Unidos, 92123
        • Rady Childrens Hosp San Diego
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • University of Colorado Hospital
    • Florida
      • Orlando, Florida, Estados Unidos, 32806
        • Arnold Palmer Children's Hospital
      • Orlando, Florida, Estados Unidos, 32827
        • Nemours Child Orlando Hem/Onc.
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Augusta Univ/Childrens Hosp-GA
      • Savannah, Georgia, Estados Unidos, 31404
        • Memorial Health University Medical Center
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60611
        • Childrens Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Indiana Hemophilia-Thromb Ctr
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, Estados Unidos, 70118
        • Children's Hosp-New Orleans
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64108
        • The Children's Mercy Hospital
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • Children's Nebraska
    • North Carolina
      • Greenville, North Carolina, Estados Unidos, 27834
        • ECU Sickle Cell Comp Clinic
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19134
        • St Christopher Hosp for Child
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Fort Worth, Texas, Estados Unidos, 76104
        • Cook Children's Hospital-Hematology-Oncology
      • Houston, Texas, Estados Unidos, 77030
        • Texas Children's Hospital_Houston
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • Pediatrics Hematology/Oncology Clinic Battle Building
      • Tallinn, Estônia, 13419
        • Tallinn Children's Hospital
      • Chambéry, França, 73000
        • Centre Hospitalier Metropole Savoie
      • Le Kremlin-Bicêtre, França, 94275
        • Ap-Hp-Hopital de Bicetre-1
      • Paris, França, 75015
        • AP-HP-HOPITAL NECKER_Service d'hématologie
      • Athens, Grécia, GR-11527
        • Aghia Sophia Childrens' Hospital
      • Thessaloniki, Grécia, GR 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Grécia, 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Catania, Itália, 95123
        • A.O.U policlinico "G. Rodolico-San Marco"
      • Florence, Itália, 50134
        • Dipartimento di Ematologia Univ. Firenze
      • Padova, Itália, 35128
        • Azienda Ospedaliera di Padova _
      • Parma, Itália, 43126
        • Azienda Ospedaliera-Universitaria Parma
      • Kanagawa, Japão, 216-8511
        • St. Marianna University School of Medicine Hospital_Pediatrics
      • Saitama, Japão, 330-8777
        • Saitama Children's Med Centre_Hematology-Oncology
      • Vilnius, Lituânia, LT-08406
        • Centre of Oncology and Hematology, Vilnius University
      • Beirut, Líbano, 961
        • Saint George Hospital University Medical Center
      • Tripoli, Líbano, 1434
        • Hospital Nini
      • Skopje, Macedônia do Norte, 1000
        • PHI University Clinic for Children's Diseases Skopje
    • Kuala Lumpur
      • Kampung Baru, Kuala Lumpur, Malásia, 50300
        • Hospital Tunku Azizah
    • Pulau Pinang
      • George Town, Pulau Pinang, Malásia, 10450
        • Hospital Pulau Pinang
    • Sarawak
      • Kuching, Sarawak, Malásia, 93586
        • Sarawak General Hospital
    • Terengganu
      • Kuala Terengganu, Terengganu, Malásia, 20400
        • Hospital Sultanah Nur Zahirah
      • Oslo, Noruega, 0372
        • Klinisk forskningspost
      • Gdansk, Polônia, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Lublin, Polônia, 20-093
        • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
      • Warsaw, Polônia, 02-091
        • Uniwersyteckie Centrum Kliniczne WUM
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polônia, 50-556
        • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
      • Birmingham, Reino Unido, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Reino Unido, BS2 8BJ
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • London, Reino Unido, WC1N 3HR
        • Great Ormond Street Hospital for Children
      • London, Reino Unido, SE1 7EH
        • Evelina London Children's Hospital - Haemophilia
      • Bucharest, Romênia, 022328
        • Clinic of Haematology, Fundeni Clinical Institute
      • Cluj-Napoca, Romênia, 400177
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Oradea, Romênia, 410469
        • Spitalul Clinic Judetean De Urgenta Bihor
      • Gothenburg, Suécia, 413 46
        • Sahlgrenska US - Koagulationscentrum
      • Bangkok, Tailândia, 10400
        • Ramathibodi Hospital
      • Bangkok, Tailândia, 10330
        • King Chulalongkorn Memorial Hospital_Bangkok_0
      • Bangkok, Tailândia, 10700
        • Siriraj Hospital - Hematology and Oncology
      • Bangkok, Tailândia, 10330
        • King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
    • Mueang Distirct,
      • Ubon Ratchathani, Mueang Distirct,, Tailândia, 34000
        • Sunpasitthiprasong Hospital_Pediatrics Department
      • Adana, Turquia (Türkiye), 01130
        • Acibadem Adana Hastanesi
      • Adana, Turquia (Türkiye), 01130
        • Acıbadem Adana Hastanesi-Hematoloji
      • Izmir, Turquia (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi
      • Izmir, Turquia (Türkiye), 35100
        • Ege Üniversitesi Hastanesi- Hematoloji
      • Samsun, Turquia (Türkiye), 55139
        • Ondokuz Mayis University Medical Faculty Ped. Haematology
      • Samsun, Turquia (Türkiye), 55139
        • Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
    • Beşevler/Ankara
      • Ankara, Beşevler/Ankara, Turquia (Türkiye), 06500
        • Gazi University
      • Ankara, Beşevler/Ankara, Turquia (Türkiye), 06500
        • Gazi Üniversitesi Hastanesi- Hematoloji
    • Gauteng
      • Parktown, Johannesburg, Gauteng, África do Sul, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
    • Assam
      • Guwahati, Assam, Índia, 781032
        • Guwahati Medical College
    • Gujarat
      • Surat, Gujarat, Índia, 395002
        • Nirmal Hospital Pvt. Ltd.
    • Maharashtra
      • Kolhāpur, Maharashtra, Índia, 416005
        • SSSH_Dept. of Clinical Haematology & Haemato Oncology
      • Mumbai, Maharashtra, Índia, 400012
        • Seth GS Medical College & KEM Hospital
      • Mumbai, Maharashtra, Índia, 400022
        • K.J Somaiya Hospital and Research Centre
      • Mumbai, Maharashtra, Índia, 400066
        • MCGM - Comprehensive Thalassemia Care
      • Pune, Maharashtra, Índia, 411004
        • Sahyadri Super Speciality Hospital
    • Odisha
      • Cuttack, Odisha, Índia, 753007
        • S.C.B. Medical College
    • Rajasthan
      • Jaipur, Rajasthan, Índia, 302004
        • J K Lon Hospital
    • Uttar Pradesh
      • Noida, Uttar Pradesh, Índia, 201303
        • Post Graduate Institute of Child Health
    • Uttart Pradesh
      • Lucknow, Uttart Pradesh, Índia, 226014
        • SGPGI

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

  • Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.

  • For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.

  • For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)

    1. Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    2. Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    3. Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
  • For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)

    1. Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
    2. Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
  • For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Ongoing or planned Immune Tolerance Induction treatment.
  • History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Concizumab-naïve patients

Concizumab-naïve participants below 12 years of age at the time of consent/assent

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Experimental: Patients coming from compassionate use

Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of patient(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: Week 32

Measured in ng/mL

Week 32
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: Week 32

Measured in nM

Week 32
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: Week 32

Measured in ng/mL

Week 32
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: Prior to the concizumab administration at week 20

Measured in ng/mL

Prior to the concizumab administration at week 20
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Prazo: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng*hr/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de março de 2022

Conclusão Primária (Real)

21 de abril de 2026

Conclusão do estudo (Estimado)

2 de novembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

15 de novembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

15 de novembro de 2021

Primeira postagem (Real)

26 de novembro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NN7415-4616
  • U1111-1247-7330 (Outro identificador: World Health Organization (WHO))
  • 2020-000504-11 (Número EudraCT)
  • jRCT2031220097 (Identificador de registro: JAPIC)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever